Clinical Trials Logo

Clinical Trial Summary

This study evaluates how children with Attention Deficit Disorder without Hyperactivity (ADD) respond to medication, and if their response is different from children who have problems with both hyperactivity and inattention. In order to do this, children ages 7-11 whose primary difficulty is with attention problems and who have never been on behavioral or psychiatric medications are being recruited. Once enrolled, children will try one week each of 3 different doses of methylphenidate, the most commonly prescribed Attention Deficit, Hyperactivity Disorder (ADHD) medication, as well as placebo. Children will be randomly assigned to one of six possible medication dose and placebo titration schedules, but the study doctor, family, and teacher will not know which dose (if any) children are receiving for a given week. Each week, behavioral and side effect ratings will be completed by both the child's parent and teacher, and the family will meet with the study doctor for a physical examination and to discuss how each week went. Some children will also have neuropsychological testing to determine how methylphenidate influences their working memory, sustained attention, and ability to inhibit (stop) inappropriate responses. All data will be analyzed to decide which medication dose the child responded to best and further recommendations for treatment will be given. Ultimately, this study aims to improve understanding of how children with ADHD-Primarily Inattentive Type respond to stimulant medications by - determining whether these children experience a diminished response to methylphenidate compared to children with both hyperactivity and inattention - determining whether certain genetic and environmental factors play a role in this response. Findings from this study will be used to help streamline the identification of the most effective doses of medication for children with ADHD-Primarily Inattentive Type.


Clinical Trial Description

Robust data indicate that stimulant medications reduce ADHD symptoms and impairment, but it is unclear whether their efficacy generalizes across the ADHD subtypes. Although predominately inattentive type (PIT) is the most prevalent ADHD subtype in U.S. population-based studies, few studies have specifically examined response to stimulants in this subtype. Instead, medication guidelines for PIT have largely been extrapolated from studies enrolling all or mostly ADHD-combined type (CT). Thus, this application seeks to improve understanding of stimulant medication response and its predictors in children with PIT. We will evaluate participants' response to methylphenidate (MPH), the most widely prescribed stimulant, via a prospective, double-blind, placebo-controlled crossover trial with 3 dose conditions. Our first specific aim is to examine MPH medication and dose response in children with PIT (n=120) and CT (n=45) to test the hypotheses that participants with PIT have a diminished MPH response and derive less benefit from higher doses compared to those with CT. Since only one prior study has examined genetic predictors of MPH response variability within PIT-only samples, our second specific aim (exploratory) is to determine the potential role of genetic polymorphisms (e.g., those in DAT1, DRD4, NET, ADRA2A, COMT, SNAP25, CES1, GRM7, LPHN3) on MPH response in children with PIT (n=120), examining both symptom change with MPH and MPH dose response curves. If we identify significant differences in MPH response between the subtypes, our findings may guide clinical practice by suggesting more effective medication strategies (such as different dosing schedules) for children with PIT. In addition, this study may yield pharmacogenetic findings that, in the future, could enable physicians to tailor individual treatment plans for children with PIT, ameliorating the current prolonged and expensive practice of prescribing by trial and error. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01727414
Study type Interventional
Source Children's Hospital Medical Center, Cincinnati
Contact
Status Completed
Phase Phase 4
Start date June 2006
Completion date July 2014

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06465641 - Methylphenidate in KBG Syndrome: N-of-1 Series Phase 4
Not yet recruiting NCT06081348 - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Phase 2
Completed NCT04799886 - Attitudes Associated to Prescription of ADHD Drugs Among Child and Adolescent Psychiatrists in Region Skåne.
Completed NCT04511169 - MyADHD-digital Training for Adults With ADHD N/A
Completed NCT05452954 - Psychosocial ADHD Interventions - Brief Parent Training N/A
Recruiting NCT03313349 - A School-Based Intervention to Improve Social Functioning N/A
Active, not recruiting NCT05930912 - Psychiatric Orders in Psychoanalytic Treatment of ASD
Recruiting NCT05924594 - Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301 Phase 3
Recruiting NCT04781972 - Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD Phase 4
Active, not recruiting NCT05286762 - Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301 Phase 3
Not yet recruiting NCT06235177 - Psychoneuromentalism Disorder: A Medical Condition That Affects People With Psychological Impairments From Health Issues Early Phase 1
Recruiting NCT04504890 - Ocular-vestibular Biomarker Identification for ADHD
Recruiting NCT06299189 - A Therapist Guided Internet-delivered Treatment for Adults With ADHD (Attention Deficit / Hyperactivity Disorder) - an Open Effectiveness Trial in Routine Care N/A
Recruiting NCT04729439 - Technology-Enhanced Executive Functioning Intervention for ADHD Phase 1
Completed NCT03335748 - the Cogmed Program for Youths With ADHD N/A
Completed NCT05631626 - Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301. Phase 3